Dupilumab
- PDF / 169,674 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 56 Downloads / 181 Views
1
Dupilumab Guttate psoriasis: case report A 40-year-old woman developed guttate psoriasis during treatment with dupilumab for atopic dermatitis (AD). The woman had AD since the age of 2 years. She had received various medications. Her skin lesions were associated with severe pruritus as well as significant impact on her quality of life. She then started receiving dupilumab [route and dosage not stated]. Following 8 weeks, a complete remission of AD was achieved. At 16 weeks of dupilumab therapy, few scattered erythematous-squamous lesions were noted on her trunk and extremities. She reported that the lesions appeared 2 weeks previously. A skin biopsy specimen revealed acanthosis, parakeratosis, hyperkeratosis, dilated capillaries and a lymphocytic infiltrate in her upper dermis. On the basis of clinical and histopathological findings, a diagnosis of guttate psoriasis was made, which was attributed to dupilumab. Therapy with dupilumab was continued. The woman was treated with betamethasone/calcipotriol [calcipotriolbetamethasone] foam. After 3 weeks, a complete remission of psoriatic lesions was observed. Author comment: "However, a triggering role of dupilumab in the development of psoriasis may not be ruled out, as the Naranjo Algorithm Score was 3, indicative of a possible relation between an observed side effect and a certain drug." Gori N, et al. A case of guttate psoriasis during treatment with dupilumab. Dermatologic Therapy 32: No. 5, Sep 2019. Available from: URL: http:// 803437467 doi.org/10.1111/dth.12998 - Italy
0114-9954/19/1782-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 7 Dec 2019 No. 1782
Data Loading...
